Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based T

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy is a phase 1/2, interventional study registered as NCT04691817 by Abramson Cancer Center at Penn Medicine, with a registry enrolment figure of 28 participants, started 2023-07-25 and due to reach its primary completion in 2026-12. Interventions recorded: Atezolizumab; Tocilizumab. Conditions listed: Lung Cancer, Nonsmall Cell. Primary outcome: Overall response rate (ORR). Lung eligibility wording from the registry: "* Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older". Sites: United States. No results are recorded here; the registry entry is the source.